CompletedNCT03582137
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
Medication studyAges 40–85United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 40 years to 85 years.
- Listed locations
- AuroraSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 5, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 74
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 40 Years to 85 Years
- Official registry ID
- NCT03582137
- Official title
Show the full official title
A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease
Get this study by email
Recruitment & locations
CompletedAurora
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Did this study involve medication?
Yes. The study involved medication, including Cannabidiol.
Who was this study for?
Listed age limits: 40 years to 85 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia